ArticleWorld journal of surgical oncology2026
Clinicopathological features and prognosis of HER2-low gastric cancer: a real-world retrospective cohort study.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHER2-low expression has recently gained considerable attention as an actionable biomarker in gastric cancer (GC). However, clinical implications of HER2-low expression in GC remains uncertain, which limited its precise management in the era of antibody‒drug conjugates. This study aims to describe the clinicopathological features and its value in predicting outcomes for GC patients.
methodWe performed a retrospective study of 994 patients (248 with HER2-low expression and 746 with HER2-zero expression) from January 2018 to December 2023. Each cohort was further divided into non-metastatic (M0) and metastatic (M1) subgroups. Clinicopathological features and survival outcomes were collected and compared between HER2-low and HER2-zero GC. Kaplan–Meier analysis and Multivariable Cox regression analyses were utilized to confirm the prognostic value. Furthermore, a nomogram was established to predict overall survival (OS) rates at 1, 2, and 3 years. The Concordance index (C-index), time-dependent receiver operating characteristic (ROC) curves and calibration curves were utilized to assess the discrimination and reliability of the Model.
resultsSignificant differences were observed in age (≥ 60 years: 65.3% vs. 55.2%, P = 0.005) and ethnicity (Hui ethnicity:12.5% vs.19.4%, P = 0.001) between the HER2-low and HER2-zero GC. HER2-low GC had lower T stage than HER2-zero GC, with T3 stage (21.8% vs. 12.5%) and T4 stage (58.1% vs.65.4%) P < 0.05. HER2-low status was identified as an independent prognostic factor associated with worse survival outcomes, particularly in patients with GC at M0 stage (HR 1.420; 95% CI 1.058–1.907). The nomogram prediction model was constructed by including these factors at M0 stage. The C-index, AUC value and calibration curves demonstrated that the nomogram performed well in predicting OS at 1, 2, and 3 years.
conclusionThe findings from the present study demonstrated that patients with HER2-low GC exhibited distinct pathological characteristics and had a worse prognosis. Further research is warranted to refine future diagnostic and treatment strategies for this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.